United Therapeutics Corporation, in collaboration with Intermountain Health, announced the world's first patient treated in a clinical study of miroliver ELAP, a bioengineered external liver assist product. This procedure marks the first human clinical trial of a manufactured organ alternative.
The procedure was performed on a patient experiencing acute liver failure who was not eligible for a liver transplant, at Intermountain Medical Center in Murray, Utah. Miroliver ELAP consists of a decellularized porcine liver scaffold recellularized with allogeneic human endothelial and liver cells.
This breakthrough represents a significant advancement in addressing the critical shortage of transplantable organs and offers a potential temporary liver support for patients with acute liver failure. The Phase 1 study of miroliver ELAP is currently underway and open for enrollment at eight sites in the United States.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.